Ziprasidone 25 mg | 99.53%
TargetMol
Ziprasidone is a united 5-HT (serotonin) and dopamine receptor antagonist which shows potent effects of antipsychotic activity.
More Information Supplier PageZiprasidone
Search Results
Tazemetostat 100 mg | 99.72%
TargetMol
Tazemetostat is an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, Tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27).
More Information Supplier PageTazemetostat
ABT-751 50 mg | 98.84%
TargetMol
ABT-751 (E7010) has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.
More Information Supplier PageABT-751
ABT-751 25 mg | 98.84%
TargetMol
ABT-751 (E7010) has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.
More Information Supplier PageABT-751
ABT-751 10 mg | 98.84%
TargetMol
ABT-751 (E7010) has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.
More Information Supplier PageABT-751
Aloxistatin 50 mg | 99.47%
TargetMol
Aloxistatin is an inhibitor of cysteine protease with blood platelet aggregation inhibiting activity. Aloxistatin is an irreversible, membrane-permeable inhibitor of lysosomal and cytosolic cysteine proteases with the ability to inhibit calpain activity in intact platelets.
More Information Supplier PageAloxistatin
Aloxistatin 2 mg | 99.47%
TargetMol
Aloxistatin is an inhibitor of cysteine protease with blood platelet aggregation inhibiting activity. Aloxistatin is an irreversible, membrane-permeable inhibitor of lysosomal and cytosolic cysteine proteases with the ability to inhibit calpain activity in intact platelets.
More Information Supplier PageAloxistatin
Tazemetostat 10 mg | 99.72%
TargetMol
Tazemetostat is an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, Tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27).
More Information Supplier PageTazemetostat
Tazemetostat 50 mg | 99.72%
TargetMol
Tazemetostat is an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, Tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27).
More Information Supplier PageTazemetostat
Tazemetostat 5 mg | 99.72%
TargetMol
Tazemetostat is an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, Tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27).
More Information Supplier PageTazemetostat